stoxline Quote Chart Rank Option Currency Glossary
  
Veru Inc. (VERU)
1.09  -0.14 (-11.29%)    05-28 15:43
Open: 1.31
High: 1.31
Volume: 3,622,927
  
Pre. Close: 1.23
Low: 1.075
Market Cap: 160(M)
Technical analysis
2024-05-28 3:25:42 PM
Short term     
Mid term     
Targets 6-month :  1.74 1-year :  2.04
Resists First :  1.49 Second :  1.75
Pivot price 1.36
Supports First :  1.07 Second :  0.89
MAs MA(5) :  1.27 MA(20) :  1.41
MA(100) :  0.84 MA(250) :  0.94
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  4.4 D(3) :  11.4
RSI RSI(14): 39.1
52-week High :  1.91 Low :  0.36
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ VERU ] has closed below the lower bollinger band by 7.4%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ VERU ] is to continue within current trading range. Bollinger Bands are 7.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.28 - 1.29 1.29 - 1.3
Low: 1.18 - 1.19 1.19 - 1.2
Close: 1.21 - 1.23 1.23 - 1.24
Company Description

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Headline News

Mon, 27 May 2024
FDA staff flags uncertainties on Veru's COVID drug; EUA hopes lift shares - Yahoo Movies Canada

Sun, 26 May 2024
Mitchell Shuster Steiner Sells 63379 Shares of Veru Inc. (NASDAQ:VERU) Stock - Defense World

Sat, 25 May 2024
Veru Inc. (VERU) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Movies UK

Sat, 25 May 2024
Veru Inc. executive purchases $6.7k in company stock - Investing.com

Sat, 25 May 2024
Veru Inc. CEO sells shares worth over $87k - Investing.com

Fri, 24 May 2024
Have Veru Insiders Been Selling Stock? - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 146 (M)
Shares Float 104 (M)
Held by Insiders 14.1 (%)
Held by Institutions 46.2 (%)
Shares Short 11,050 (K)
Shares Short P.Month 9,500 (K)
Stock Financials
EPS -0.7
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.34
Profit Margin 0 %
Operating Margin -411.2 %
Return on Assets (ttm) -51.1 %
Return on Equity (ttm) -124.6 %
Qtrly Rev. Growth -14.7 %
Gross Profit (p.s.) 0
Sales Per Share 0.1
EBITDA (p.s.) -0.52
Qtrly Earnings Growth 0 %
Operating Cash Flow -60 (M)
Levered Free Cash Flow -40 (M)
Stock Valuations
PE Ratio -1.58
PEG Ratio -0.1
Price to Book value 3.14
Price to Sales 10.1
Price to Cash Flow -2.71
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android